CA3212386A1 - Variants de ferritine ayant une stabilite et une capacite de complexation accrues - Google Patents

Variants de ferritine ayant une stabilite et une capacite de complexation accrues Download PDF

Info

Publication number
CA3212386A1
CA3212386A1 CA3212386A CA3212386A CA3212386A1 CA 3212386 A1 CA3212386 A1 CA 3212386A1 CA 3212386 A CA3212386 A CA 3212386A CA 3212386 A CA3212386 A CA 3212386A CA 3212386 A1 CA3212386 A1 CA 3212386A1
Authority
CA
Canada
Prior art keywords
seq
ferritin
amino acid
polypeptide
trbd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3212386A
Other languages
English (en)
Inventor
Alessandro ARCOVITO
Alessandra BONAMORE
Alberto BOFFI
Ilona MARSZALEK
Marcin SKORZYNSKI
Tomasz RYGIEL
Magdalena Krol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellis AG
Original Assignee
Cellis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2021/056996 external-priority patent/WO2021185986A1/fr
Application filed by Cellis AG filed Critical Cellis AG
Publication of CA3212386A1 publication Critical patent/CA3212386A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un polypeptide variant de ferritine, dans lequel au moins un résidu lysine est supprimé ou substitué par un acide aminé non basique. L'invention concerne en outre un complexe de ce polypeptide et d'une étiquette ou d'un médicament et un système d'administration cellulaire isolé comprenant le polypeptide ou le complexe de l'invention, ainsi que des utilisations de ce système pour la prophylaxie, la thérapie, le diagnostic ou la théragnostique, en particulier pour la thérapie d'un cancer ou de maladies inflammatoires.
CA3212386A 2021-03-18 2022-03-18 Variants de ferritine ayant une stabilite et une capacite de complexation accrues Pending CA3212386A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2021/056996 2021-03-18
PCT/EP2021/056996 WO2021185986A1 (fr) 2020-03-18 2021-03-18 Variants de ferritine présentant une stabilité, une aptitude à la complexation et une affinité pour le récepteur de transferrine accrues
PCT/EP2022/057205 WO2022195092A1 (fr) 2021-03-18 2022-03-18 Variants de ferritine ayant une stabilité et une capacité de complexation accrues

Publications (1)

Publication Number Publication Date
CA3212386A1 true CA3212386A1 (fr) 2022-09-22

Family

ID=81325941

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3212386A Pending CA3212386A1 (fr) 2021-03-18 2022-03-18 Variants de ferritine ayant une stabilite et une capacite de complexation accrues

Country Status (2)

Country Link
CA (1) CA3212386A1 (fr)
WO (1) WO2022195092A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024133541A1 (fr) * 2022-12-20 2024-06-27 Cellis Sp. Z O.O. [Ltd.] Système isolé d'administration ciblée pour le traitement du cancer de l'ovaire

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
PL1896040T3 (pl) 2005-06-29 2012-12-31 Threshold Pharmaceuticals Inc Proleki alkilatora fosforoamidowego
ES2884044T3 (es) 2006-12-26 2021-12-10 Immunogenesis Inc Profármaco alquilante de fosforamidato para el tratamiento del cáncer
WO2017222398A1 (fr) * 2016-06-22 2017-12-28 Cellis Sp. Z O.O. Système de distribution d'étiquettes ou de substances pharmaceutiquement actives à ciblage cellulaire
JP6983808B2 (ja) * 2016-01-08 2021-12-17 メディトープ バイオサイセンシーズ インク.Meditope Biosciences, Inc. 自己架橋性抗体
CN109803642B (zh) * 2016-07-15 2022-10-14 韩国科学技术研究院 新型纳米笼及其用途

Also Published As

Publication number Publication date
WO2022195092A1 (fr) 2022-09-22

Similar Documents

Publication Publication Date Title
US20220280663A1 (en) Cellular targeted pharmaceutically active substance or label delivery system
WO2017222398A1 (fr) Système de distribution d'étiquettes ou de substances pharmaceutiquement actives à ciblage cellulaire
TW201805012A (zh) 利用前列腺癌相關抗原之腫瘤疫苗接種之組合物及方法
US20240158472A1 (en) Ferritin variants with increased stability and complexation ability
CA3212386A1 (fr) Variants de ferritine ayant une stabilite et une capacite de complexation accrues
Choi et al. Nanocages displaying SIRP gamma clusters combined with prophagocytic stimulus of phagocytes potentiate anti-tumor immunity
US20240060045A1 (en) Cellular targeted active ingredient delivery system
WO2024056413A1 (fr) Système isolé d'administration ciblée pour le traitement du gliome
WO2024133541A1 (fr) Système isolé d'administration ciblée pour le traitement du cancer de l'ovaire
WO2023034229A1 (fr) Point de contrôle immunitaire ciblant des nanoparticules thérapeutiques
KR20230143955A (ko) 신규 종양 항원-표적 항암제
WO2023064793A1 (fr) Protéines de fusion de l'interleukine 7 et de l'interleukine 21